Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
By S. Ostrand-Rosenberg, P. Sinha. Journal of Immunology, 2009
1,555 citations recorded by the source corpus.
Many cancer immunotherapies developed in experimental animals have been tested in clinical trials. Although some have shown modest clinical effects, most have not been effective. Recent studies have identified myeloid-origin cells that are potent suppressors of tumor immunity and therefore a significant impediment to cancer immunotherapy. “Myeloid-derived suppressor cells” (MDSC) accumulate in the blood, lymph nodes, and bone marrow and at tumor sites in most patients and experimental animals with cancer and inhibit both adaptive and innate immunity. MDSC are induced by tumor-secreted and host-secreted factors, many of which are proinflammatory molecules. The induction of MDSC by proinflammatory mediators led to the hypothesis that inflammation promotes the accumulation of MDSC that down-regulate immune surveillance and antitumor immunity, thereby facilitating tumor growth. This article reviews the characterization and suppressive mechanisms used by MDSC to block tumor immunity and describes the mechanisms by which inflammation promotes tumor progression through the induction of MDSC.
Subfields: Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/2060147f070ef10fbeeec21b04d794456b54078e
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
- D. Gabrilovich
- J. Massagué
- T. Condamine
- Je-in Youn
- E. Tcyganov
- Vinit Kumar
- Sima Patel
- Cesar A. Corzo
In Oncology
- R. Weinberg
- D. Hanahan
- J. Massagué
- Larry Norton
- Thordur Oskarsson
- A. Rustgi
- D. Bar-Sagi
- Y. Pylayeva-Gupta
Citations in the corpus
- The nature of myeloid-derived suppressor cells in the tumor microenvironment (2016, background): “MDSC can also produce immunosuppressive cytokines, such as IL-10 and TGF-b [48], induce T regulatory cells (Tregs) [49], affect NK cell function [50] and use other suppressive mechanisms (Figure 1).”
- A CXCL1 paracrine network links cancer chemoresistance and metastasis (2012, positive): “In line with our hypothesis, CD11b + Gr1 + cells and specifically the CD11b + Ly6G + subpopulation expressed CXCR2 (Figures 2E and S2Q).”
- FAP Promotes Immunosuppression by Cancer-Associated Fibroblasts in the Tumor Microenvironment via STAT3-CCL2 Signaling. (2016, background): “Abundant presence of myeloid-origin cells, particularly myeloid-derived suppressor cells (MDSCs) including PMN-MDSCs and M-MDSCs, is a hallmark of tumor-promoting inflammation, and implicated in directly promoting tumor progression primarily by their potent immunosuppressive activities (26,27).”
- Hallmarks of cancer: the next generation. (2011, positive): “Of particular interest, a class of tumor-infiltrating myeloid cells (defined as coexpressing the macrophage marker CD11b and the neutrophil marker Gr1) has been shown to suppress CTL and NK cell activity, having been independently identified as MDSCs (Qian and Pollard, 2010; Ostrand-Rosenberg and Si”
- Myeloid derived suppressor cells (2013, background): “These include reactive oxygen species (ROS) production, TGFβ production, cysteine depletion, CD62L downregulation, and other non-T cell-specific effects.(3) ROS production likely occurs via the NADPH oxidase machinery present in all phagocytic cells.”
- Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. (2010, neutral): “The induction of myeloid-derived suppressor cells (MDSC) is shown to be an important immune-evading strategy used by tumors (45, 46).”